The purpose of this study is to evaluate the safety, tolerability pharmacokinetics and pharmacodynamics of SAL0140 healthy Chinese population.
Subjects has fully understood and voluntarily signed the informed consent form, and is able to comply with the requirements and restrictions listed in the informed consent form;
Male or female aged 18-65 years (including 18 and 65 years old);
Male body weight ≥50kg, female body weight ≥45kg and body mass index (BMI) between 19.0 - 26.0 kg/m2 (including 19.0 and 26.0, BMI = weight(kg) / height(cm)2) at screening;
All examinations (including physical examination, vital signs, laboratory tests, ECG, chest X-ray (anterior and lateral views), etc.) show no abnormalities or minor abnormalities deemed non clinical signiant by the investigator;
Subjects with orthostatic tachycardia or orthostatic hypotension at screening; or those with a history of orthostatic hypotension symptoms (such as dizziness, fatigue, blurred vision, pallor upon standing) or orthostatic tachycardia symptoms (such as dizziness, palpitations, tremors, general weakness, blurred vision, exercise intolerance when standing);
Subjects have used corticosteroids within 3 months prior to dosing;
Subjects with personal or family history of long QT syndrome, torsades de pointes, or other complex arrhythmias, or family history of sudden death;
Subjects with prolonged QTcF interval (>450msec) on ECG;
Parallel
SAL0140
DrugIn this part, SAL0140 tablets will be administered as a single or multiple oral dose.
SAL0140 placebo
DrugIn this part, SAL0140 placebo tablets will be administered as a single or multiple oral dose.
The rate of Adverse events
The rate of Adverse events occur during the whole study
The rate of normality or abnormality of electrocardiogram
The rate of normality or abnormality of electrocardiogram during the whole study
Click on the lead sponsor to view all of their trials.
